Abstract
Purpose: To investigate functional and morphological changes in patients with chronic central serous chorioretinopathy after supplementation with antioxidants containing lutein or a placebo. Procedures: One hundred eyes of 100 patients were randomly divided into 2 groups, one taking tablets with lutein plus other antioxidants and the other taking a placebo for 6 months. Best-corrected visual acuity (BCVA) and the subfoveal fluid height on optical coherence tomography were measured. Results: Seventy-nine patients (37 in the supplementation and 42 in the placebo group) completed the 6-month follow-up. In the supplementation group, mean BCVA showed significant improvement (p = 0.003), while there was no significant change in the placebo group (p = 0.589). The mean subfoveal fluid height was significantly reduced, by 28.6%, in the supplementation group (p = 0.028), in contrast to 3.3% in the placebo group (p = 0.898). Conclusions: Antioxidant supplementation significantly reduced subfoveal fluid height. The impacts of antioxidant supplementation on BCVA remain to be elucidated in future studies.
| Original language | English |
|---|---|
| Pages (from-to) | 159-166 |
| Number of pages | 8 |
| Journal | Ophthalmologica |
| Volume | 237 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Apr 1 2017 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Ophthalmology
- Sensory Systems
Cite this
A multicenter randomized controlled study of antioxidant supplementation with lutein for chronic central serous chorioretinopathy. / Shinojima, Ari; Sawa, Miki; Sekiryu, Tetsuju; Oshima, Yuji; Mori, Ryusaburo; Hara, Chikako; Sugano, Yukinori; Kato, Aki; Asato, Hitomi; Yuzawa, Mitsuko; Gomi, Fumi; Ogura, Yuichiro; Ishibashi, Tatsuro; Nanri, Tomoaki; Yasukawa, Tsutomu.
In: Ophthalmologica, Vol. 237, No. 3, 01.04.2017, p. 159-166.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A multicenter randomized controlled study of antioxidant supplementation with lutein for chronic central serous chorioretinopathy
AU - Shinojima, Ari
AU - Sawa, Miki
AU - Sekiryu, Tetsuju
AU - Oshima, Yuji
AU - Mori, Ryusaburo
AU - Hara, Chikako
AU - Sugano, Yukinori
AU - Kato, Aki
AU - Asato, Hitomi
AU - Yuzawa, Mitsuko
AU - Gomi, Fumi
AU - Ogura, Yuichiro
AU - Ishibashi, Tatsuro
AU - Nanri, Tomoaki
AU - Yasukawa, Tsutomu
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Purpose: To investigate functional and morphological changes in patients with chronic central serous chorioretinopathy after supplementation with antioxidants containing lutein or a placebo. Procedures: One hundred eyes of 100 patients were randomly divided into 2 groups, one taking tablets with lutein plus other antioxidants and the other taking a placebo for 6 months. Best-corrected visual acuity (BCVA) and the subfoveal fluid height on optical coherence tomography were measured. Results: Seventy-nine patients (37 in the supplementation and 42 in the placebo group) completed the 6-month follow-up. In the supplementation group, mean BCVA showed significant improvement (p = 0.003), while there was no significant change in the placebo group (p = 0.589). The mean subfoveal fluid height was significantly reduced, by 28.6%, in the supplementation group (p = 0.028), in contrast to 3.3% in the placebo group (p = 0.898). Conclusions: Antioxidant supplementation significantly reduced subfoveal fluid height. The impacts of antioxidant supplementation on BCVA remain to be elucidated in future studies.
AB - Purpose: To investigate functional and morphological changes in patients with chronic central serous chorioretinopathy after supplementation with antioxidants containing lutein or a placebo. Procedures: One hundred eyes of 100 patients were randomly divided into 2 groups, one taking tablets with lutein plus other antioxidants and the other taking a placebo for 6 months. Best-corrected visual acuity (BCVA) and the subfoveal fluid height on optical coherence tomography were measured. Results: Seventy-nine patients (37 in the supplementation and 42 in the placebo group) completed the 6-month follow-up. In the supplementation group, mean BCVA showed significant improvement (p = 0.003), while there was no significant change in the placebo group (p = 0.589). The mean subfoveal fluid height was significantly reduced, by 28.6%, in the supplementation group (p = 0.028), in contrast to 3.3% in the placebo group (p = 0.898). Conclusions: Antioxidant supplementation significantly reduced subfoveal fluid height. The impacts of antioxidant supplementation on BCVA remain to be elucidated in future studies.
UR - http://www.scopus.com/inward/record.url?scp=85011837380&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011837380&partnerID=8YFLogxK
U2 - 10.1159/000455807
DO - 10.1159/000455807
M3 - Article
C2 - 28171877
AN - SCOPUS:85011837380
VL - 237
SP - 159
EP - 166
JO - Ophthalmologica
JF - Ophthalmologica
SN - 0030-3755
IS - 3
ER -